Hypothermia is not therapeutic in a neonatal piglet model of inflammation-sensitized hypoxia ischemia

Kathryn A Martinello[1,2],

Christopher Meehan[1],

Adnan Avdic-Belltheus[1],

Ingran Lingam[1],

Tatenda Mutshiya[1],

Qin Yang[1],

Mustafa Ali Akin[3],

David Price[4],

Magdalena Sokolska[4],

Alan Bainbridge[4],

Mariya Hristova[1],

Ilias Tachtsidis[5],

Cally J Tann[6],

Donald Peebles[1],

Henrik Hagberg[7,8],

Tim GAM Wolfs[9],

Nigel Klein[10],

Boris W Kramer[9],

Bobbi Fleiss[11,12],

Pierre Gressens[12],

Xavier Golay[13],

Nicola J Robertson[1,14,*]

[1]Institute for Women's Health, University College London, London, United Kingdom

[2]Robinson Research Institute, University of Adelaide, Adelaide, South Australia, Australia

*Corresponding author: Professor Nicola J Robertson, 74 Huntley Street, Institute for Women's Health, London, WC1E 6HX, n.robertson@ucl.ac.uk, Phone: 07779 248 235, Fax: 020 3108 20362.

[3]Department of Paediatrics, Ondokuz Mayıs University, Samsun, Turkey

[4]Medical Physics and Biomedical Engineering, University College London NHS Foundation Trust, London, United Kingdom

[5]Medical Physics and Biomedical Engineering, University College London, London, United Kingdom

[6]Adolescent, Reproductive and Child Health Centre, London School of Hygiene and Tropical Medicine, London, United Kingdom

[7]Centre of Perinatal Medicine and Health, Department of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden

[8]Centre for the Developing Brain, Kings College London, London, United Kingdom

[9]Department of Pediatrics, University of Maastricht, Maastricht, Netherlands

[10]Paediatric Infectious Diseases & Immunology, Institute of Child Health, University College London, London, United Kingdom

[11]School of Health and Biomedical Sciences, RMIT University, Melbourne, Australia

[12]Université de Paris, NeuroDiderot, Inserm, Paris, France

[13]Institute of Neurology, University College London, London, United Kingdom

[14]Centre for Clinical Brain Sciences, University of Edinburgh

Abstract

Background—Perinatal inflammation combined with hypoxia-ischemia exacerbates injury in the developing brain. Therapeutic hypothermia is standard care for neonatal encephalopathy, however it's benefit in inflammation-sensitized hypoxia-ischemia (IS-HI) is unknown.

Methods—12 newborn piglets received a 2μg/kg bolus and 1μg/kg/h infusion over 52h of E. *Coli* LPS. HI was induced 4h after LPS bolus. After HI, piglets were randomized to hypothermia (HT, 33.5°C 1-25h after HI, n=6) or normothermia (NT, n=6). aEEG was recorded and magnetic resonance spectroscopy (MRS) acquired at 24 and 48h. At 48h TUNEL-positive brain cell death, microglial activation/proliferation, astrogliosis and cleaved caspase-3 (CC3) were quantified. Hematology and plasma cytokines were serially measured.

Results—Two HT piglets died. aEEG recovery, thalamic and white matter MRS Lactate/N-Acetylaspartate and TUNEL-positive cell death were similar between groups. HT increased microglial activation in the caudate, but had no other effect on glial activation/proliferation. HT reduced CC3 overall. HT suppressed platelet count and attenuated leucocytosis. Cytokine profile was unchanged by HT.

Conclusions—We did not observe protection with HT in this piglet IS-HI model based on aEEG, MRS and immunohistochemistry. Immunosuppressive effects of HT and countering neuroinflammation by LPS may contribute to the observed lack of HT efficacy. Other immunomodulatory strategies may be more effective in IS-HI.

Introduction

Therapeutic hypothermia (HT) is standard care for neonates with intrapartum-related neonatal encephalopathy (NE) under intensive care settings. Cooling to 33.5°C for 72h improves survival free from disability in the short and long term(1, 2). However, cooling is ineffective in preventing disabilities in a proportion of infants (number needed to treat 7 (95% CI 5-10) for reduction in death or neurodisability at 18 months) (1). It is clear that, while disability from cerebral palsy (CP) in NE survivors reduces from 35% (1) to as low as 16% (3) with HT, some level of intellectual impairment may remain even in the absence of CP (4). Attenuated efficacy of HT may be due to severity of illness, timing of insult in relation to initiation of HT, or sensitization with co-existing infection/inflammation.

In preclinical laboratory studies demonstrating HT efficacy, NE is typically modelled with hypoxic-ischemic (HI) brain injury. However, in the clinical setting, the etiology of NE is multifactorial, with contributions from antenatal and placental pathology (5), genetic susceptibility (6) and perinatal infection/inflammation (7) in addition to sentinel HI events (8). Pre-clinical (7, 9, 10) and clinical (11) studies suggest that acute infection/inflammation sensitizes the brain to subsequent HI, lowering the injury threshold and worsening outcome (7, 12). Mortality amongst infants with combined NE and infection is increased compared with NE alone (13). We have recently demonstrated an increase in mortality and brain cell death in *Escherichia Coli* (E. *coli*) LPS sensitized hypoxic brain injury in the piglet model, compared with either E. *coli* LPS or hypoxia alone (10). These data concur with studies of small animal models of inflammation-sensitized HI (IS-HI) (9, 14, 15). Given the increase in severity of brain injury and mortality, effective therapeutic interventions are urgently needed for infants with IS-HI.

The benefit and safety of cooling infants with IS-HI is unclear. HT induces alterations in leucocyte number, microglial cell (16) activation (17), cytokine/chemokine profiles (18) and hemodynamics (19); it is plausible that immunomodulatory effects of HT may not be beneficial in the context of inflammation-sensitisation. In a small prospective study of placental histology relative to MRI outcomes, HT was less protective for infants with NE where placental histology showed chorioamnionitis (20). In low-resource settings, where rates of IS-HI are high, HT may be less effective, and potentially harmful (21, 22). In addition, HT has been shown to be deleterious in the presence of meningitis (23) and sepsis (24) in adult clinical studies. These observations emphasize the critical need for pre-clinical animal models that assess safety and efficacy of HT and other neuroprotective agents in IS-HI. Rodent IS-HI models suggest variable, pathogen dependent, efficacy of HT (14, 15, 25). This has not previously been examined in a large animal model.

The aim of the study was to assess safety and efficacy of HT in an E. *coli* LPS-sensitized HI piglet model. The piglet model has strong similarities to newborn infants with NE in terms of the evolution and pattern of injury after HI and neuropathology (26, 27). We hypothesized that HT would not provide neuroprotection in IS-HI based on our primary outcome measures: (i) amplitude integrated electroencephalogram (aEEG) background activity recovery over 48 h; (ii) Proton (^{1}H) magnetic resonance spectroscopy (MRS) Lactate/N-acetyl aspartate ratio (Lac/NAA) at 48h in the subcortical white matter and

thalamus; and (iii) TUNEL immunolabelling of histological cell death over the whole brain and 8 brain regions at 48h after HI.

Methods

This study was conducted in accordance with the UK Home Office Guidelines [Animals (Scientific procedures) Act, 1986] and complies with ARRIVE guidelines. The Ethics Committee of University College London approved the study.

Sample size calculation

Using previous data from our piglet study of LPS plus hypoxia (geometric least square mean standard deviation of 17) we estimated that 6 piglets per intervention group were required to detect a difference in TUNEL-positive cells of greater than 30 cells/mm^2, using a significance threshold of 5% and 80% power.

Animal experiments and surgical preparation

Male Large White piglets aged <36h were sedated with intramuscular midazolam (150μg) and anaesthetized with 2-3%v/v isoflurane. Piglets underwent tracheostomy and mechanical ventilation (SLE 2000 infant ventilator, Surrey, UK). The bilateral common carotid arteries were surgically isolated and encircled by inflatable occluders (OC2A, In Vivo Metric). A 2 French central venous catheter (Vygon, Swindon, UK) was inserted into the axillary or brachial vein for later infusion of LPS. Umbilical catheters were sited; a 4 French double-lumen umbilical venous catheter (Vygon) used for maintenance fluids (10% dextrose, 60ml/kg/day, reduced to 40ml/kg/day post HI), fentanyl (3μg/kg/h) and antibiotics (benzylpenicillin 50mg/kg every 12h and gentamicin 2.5mg/kg every 24 h); and a 2.5 French umbilical arterial catheter (Vygon) for intermittent blood sampling (Abbot Laboratories, UK) and continuous monitoring of heart rate and mean arterial blood pressure (MABP). Arterial catheters were maintained with 0.3ml/h heparinized saline (1IU/ml in 0.9% saline solution). Core (rectal) temperature was maintained in the normothermic range during surgery using a radiant warmer. Duration of surgery was 1-2 h.

Following surgery, piglets were positioned prone within a bespoke MRI compatible transport incubator. Intensive care support and physiological monitoring (SA instruments, London, UK) was continued throughout the study. Ventilation was adjusted to maintain partial pressure of oxygen (PaO2) and carbon dioxide (PaCO2) at 8–13 kPa and 4.5–6.5 kPa, respectively. MABP was supported with crystalloid (0.9% saline, Baxter, 10ml/kg bolus) and inotropes (dopamine 5-25μg/kg/min, dobutamine 5-20μg/kg/min, noradrenaline 0.1-1 μg/kg/min, adrenaline 0.1-1μg/kg/min) to target MABP >35 mmHg. Anaesthesia was maintained throughout with fentanyl (3μg/kg/h infusion) and isoflurane (2-3%). Hyperkalemia (Potassium >7.0 mmol/l) was treated with 4μg/kg intravenous salbutamol over 10 min.

EEG acquisition

Multichannel six-lead EEG (Nicolet, CareFusion, Madison, WI) was commenced immediately post-surgery and maintained throughout the study. aEEG recordings were

retrospectively scored hourly using the pattern classification (28). Flat trace was assigned a score of 0; continuous low voltage 1; burst suppression 2; discontinuous normal voltage 3; and continuous normal voltage 4. Scores were averaged every 6 h. Electrographic seizures were treated with Phenobarbitone, initially 20mg/kg, followed by 10mg/kg doses for subsequent seizures, up to a maximum 40mg/kg.

Broadband Near-infrared Spectroscopy

A broadband near-infrared spectroscopy (bNIRS) system (Mini-CYRIL, Cytochrome Research Instrument and Application System, UCL, UK) was used to measure the concentration of oxidized cytochrome-c-oxidase (oxCCO).

LPS administration

Baseline physiological, bNIRS and EEG data were captured prior to administration of LPS. All piglets received a bolus of 2μg/kg LPS (E. *coli*-derived, Sigma LPS O55:B5, St Louis, MO) followed by a continuous infusion of 1μg/kg/h LPS for the duration of the experiment (total 52h LPS).

Transient Hypoxia Ischemia

Four hours after the LPS bolus, the carotid occluders were inflated and the fraction of inspired oxygen (FiO_2) reduced to induce transient HI. FiO_2 was decreased sequentially to 6% over the first 3 min and maintained. The insult was titrated using continuous MABP, EEG and bNIRs monitoring, and arterial blood gas measurements at 5-min intervals. Target insult parameters included MABP between 26 to 30mmHg, a 3-fold reduction in oxCCO from baseline, a sustained isoelectric EEG and metabolic acidosis (pH <7.3, Lactate >10). FiO_2 was liberalized in the event of MABP and oxCCO values beyond the target range. The duration of insult was anticipated to be 20 min. At the end of insult, occluders were deflated, FiO_2 normalized to 21%, and the animal resuscitated as necessary.

Experimental groups – Temperature management

Following insult, piglets were randomized, using a computer-generated randomization sequence and opaque sequentially-numbered envelopes, to two groups: i. LPS, HI and Normothermia (NT), and ii. LPS, HI and Hypothermia (HT) (Figure 1). NT piglets had core temperature maintained in the normothermic range (38.0 - 39.0°C) throughout the study. HT piglets were actively cooled to 33.5°C from 1 - 25h post insult, then rewarmed over 10h at an incremental rate of 0.5°C/h (17). HT piglets were subsequently maintained in the normothermic range until the end of the study. Temperature was maintained within target ranges using a water mattress (Tecotherm TSmed200, Inspiration Healthcare, Crawley, UK) manually adjusted according to continuous rectal temperature. The mattress was wrapped around the trunk and limbs.

Magnetic resonance spectroscopy (MRS)

MRS was acquired on a Philips Achiever 3T (Philips Healthcare, Best, Netherlands) scanner at 24h and 48h after HI. [1]H magnetic resonance spectra were acquired using a Philips 32-channel head coil. Chemical shift imaging (CSI) was based on a 2D-PRESS excitation

used an 8 x 8 matrix with a voxel size of 7.5 x 7.5mm and slab thickness of 10mm. Repetition time was 2 sec and the echo time was 288 ms. ^{1}H CSI data was processed using spectroscopy analysis software, TARQUIN (29) yielding signal amplitudes for NAA and lactate. Two regions were selected for the final analysis: a single voxel over the dorsal right subcortical white matter at the centrum semi-ovale level and the sum of two voxels over the lateral thalami.

Hematology and Cytokine analysis

Arterial blood was collected at baseline, 4h after LPS bolus, at end of HI and at 3, 12, 24 and 48h post HI. Cerebrospinal fluid (CSF) was obtained by lumbar puncture at baseline and at 48 h. Hematology samples were stored at 4°C for a maximum of 72h prior to complete blood film examination (Royal Veterinary College Diagnostic Laboratory, Hawkshead Campus, UK). Hemoglobin (Hb), total white cell (WBC), neutrophil, lymphocyte, monocyte and platelet count were analyzed. Serum and CSF samples were frozen (-20°C) for later protein analysis. Multiplex porcine ELISA was undertaken to quantify IL-1β, IL-6, IL-8 and TNFα (Q-Plex Porcine Cytokine - High sensitivity (4-Plex), ref: 119149PC, Tebu-Bio, France) while a porcine ELISA was utilized for IL-10 (Porcine IL-10 ELISA Kit (Cloud-Clone Corp., ref. SEA056Po) Tebu-Bio, France).

Brain Histology

Forty-eight hours after HI, piglets were euthanized and histological brain specimens obtained and prepared as previously described (10). Cell death was quantified by nuclear DNA fragmentation using histochemistry with Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL). Glial activation was quantified using presence of astrocyte Glial Fibrillary Acidic Protein (GFAP) and microglial Ionized Calcium-Binding Adaptor Molecule (IBA-1) immunoreactivity. Cleaved Caspase-3 (CC3) immunoreactivity was quantified. Histological analysis was performed by investigators blind to treatment group. Eight brain regions were assessed (cingulate cortex, sensorimotor cortex, hippocampus, periventricular white matter, internal capsule, caudate nucleus, putamen and thalamus). For each region, TUNEL positive nuclei were counted in six fields (3 per section, at x40 magnification, with an area of 0.066 mm^2) and the average converted into counts per mm^2. IBA-1 positive cell body count was similarly performed. In addition, IBA1 ramification index was calculated in six fields per region, at x40 magnification, using a 0.049 mm x 0.049 mm square grid. The microglial ramification index was calculated as (B^2/C), where C is the number of cell bodies within the grid, and B is the number of branches crossing the 3 horizontal and 3 vertical gridlines. CC3 immunoreactive cells were counted in four fields per region (at ×20 magnification with an area of 0.164mm^2) and the average converted into counts per mm^2. To quantify the GFAP immunoreactivity optical luminosity values were calculated by deducting mean brightness values of the tissue (four fields per region at x20 magnification) from the mean brightness of the blank slide.

Statistical methods

Non-normally distributed data was log transformed prior to analysis. Using SAS JMP® Pro v14.0.0, analysis of variance models were fitted to give estimates of expected treatment group mean values and difference between means. For TUNEL and histology measurements,

the effects of Treatment, Region and the interaction between them were fitted to the mean result for each subject averaged across replicate measurements within each region. For EEG, MRS, cytokines and hematology, a model with terms for Treatment, Time Interval (as a factor) and the interaction between them, and a random subject effect to take into account the repeated measures structure, was fitted to the results for each subject averaged across each time interval. Using the model, a comparison to baseline was calculated for hematology values. GraphPad Prism® v8 was used to calculate Pearson's correlation between TUNEL and CC3 cell count. Cytokine change from baseline was calculated using Wilcoxon matched-pairs signed rank test. Using IBM SPSS® v22, physiological data and clinical outcomes were analyzed using t-test or Fisher's Exact test as appropriate.

Results

Baseline characteristics and physiological parameters

Piglet weight ranged from 1800g to 2250g. Physiological parameters are shown in Table 1. At baseline groups were similar. During the time epochs 1 – 25h and 25 – 35 h, which encompasses cooling and rewarming, the HT subjects had lower core temperatures as expected (p<0.001 and 0.002 respectively).

Hypoxic Ischemic insult

Insult severity, as determined by duration of insult, MABP <30, isoelectric EEG, AUC FiO_2, AUC oxCCO and end HI acid-base status, was similar between groups (Table 2).

Survival and clinical illness severity

During active cooling, HT animals had lower mean heart rate than NT animals (171 (SD 25) bpm compared with 235 (SD 21) bpm, p=0.001). Mean heart rate was also lower during rewarming for HT animals (p=0.02) (Table 1). Mean MABP, inotropic support and saline bolus requirement was not different between groups (Table 3). Mean infusion rates of all inotropes were higher in the HT group, however confidence intervals are wide. HT had higher mean blood glucose at 24h (10.3 (SD 3.6) mmol/L compared with 6.5 (SD 1.2) mmol/L p=0.033). Three of six NT and four of six HT subjects had hyperkalemia necessitating treatment (p=0.5).

Two of six piglets died prior to experiment completion in the HT group, compared with none in the NT group (p=0.23). The 2 animals had refractory hypotension and worsening metabolic acidosis at the time of cardiac arrest (30 and 33 h). Both were rewarmed early due to severity of hypotension (at 16 and 12.5 h). One had severe hyperkalemia (K^+ >9). Both had macroscopic necrosis to abdominal solid organs including the liver, kidneys and bowel.

TUNEL

Mean whole brain TUNEL positive cell counts were similar between the NT and HT groups (p=0.97) (Figure 2A). Regional assessment was also similar between groups. There was a trend towards greater histological cell death in the internal capsule for the TH group (p=0.064).

Cleaved Caspase 3

HT reduced overall CC3 (Figure 2B) compared with NT (p=0.04). Regional analysis demonstrates lower CC3 in the internal capsule, caudate nucleus and hippocampus (p=0.006, p=0.01 and p=0.02 respectively). There was no correlation between TUNEL positive cell count and CC3 positive cell count (r = -0.42 95% CI -0.54 to -0.30).

GFAP

Mean whole brain and regional GFAP luminosity was similar between the NT and HT groups (p=0.89) (Figure 2B).

IBA1

IBA1 positive cell count was no different between the NT and HT group throughout the whole brain (p=0.41) and in each brain region (p 0.08) (Figure 2B). Overall microglial activation state (ramification index) was also similar between groups (p=0.81). There was an increase in microglial activation (lower ramification index) in the caudate nucleus with HT (p=0.029). Microglia for both groups appeared partially activated, with enlarged cell bodies, a reduced number of processes and thickening of the remaining processes.

Representative photomicrographs from the internal capsule area at 40x magnification for all histological stains are shown in Figure 2C.

aEEG

All subjects had a normal (score 4) aEEG at baseline (Figure 3). Mean aEEG score for both groups was suppressed following HI and remained suppressed throughout the experiment. There was no effect of hypothermia on aEEG recovery. 2/6 NT and 1/6 HT piglets had electrographic seizures (p=0.5). Seizure onset was at 12 and 15h post HI for the two NT piglets, and at 36h for the one HT piglet with seizures. Seizure burden was no different between groups (range 0 - 47 min) (p=0.75). 3/6 NT and 1/6 HT piglets were treated with phenobarbitone. Phenobarbitone use and dose/kg was not different between groups (p 0.34).

MRS

Lac/NAA was no different between the cooled and normothermic piglets at either time point, in either the white matter or thalamus (Figure 4, p 0.35 for all comparisons). Note that due to early death, two of six HT subjects were not scanned at 48 h. Compared to all others, these two deceased piglets had the highest thalamic Lac/NAA at 24 h.

Hematology

In both groups, platelet count fell below baseline by time 0 (p 0.024) (Figure 5). NT platelet count returned to baseline levels, before a late thrombocytosis at 48h post HI (p<0.001). HT platelet count continued to fall below baseline for the duration of cooling therapy (p 0.007), before a later recovery to baseline at 48 h. At 24 and 48h after HI, platelet count was suppressed in the HT group compared with NT (p=0.005 and p 0.001 respectively).

The WBC increased from baseline for NT subjects at 3, 12 and 24h (p 0.016) (Figure 5). This increase was attenuated in HT subjects. There was no significant difference between

WBC for NT and HT animals at any single time point. Neutrophils were the predominant leucocyte present and analysis closely mirrored that for WBC. There was no effect of cooling or time on lymphocyte number. The monocyte count was raised at 24h in the HT group compared to baseline (p=0.002). Monocytes were otherwise unaltered by HT or time.

There was no intergroup difference for Hb at any time point. NT Hb was stable then fell below baseline from 24h (p=0.002). Hb increased from baseline in the HT group at 4h after LPS and at 3 and 12h after HI (p 0.012) (Figure 5). At 48 h, both HT and NT Hb were below baseline (p 0.022).

Cytokines

The pattern of IL-6, IL-8 and TNFα in the plasma and CSF is shown in Figure 6. Plasma IL-6, IL-8 and TNFα increased from baseline pre-HI (p 0.0034) in response to LPS. HT plasma IL-6 was higher than NT at 3h post-HI (p=0.018). There were no other differences between groups and no difference in CSF cytokines. IL-1β and IL-10 were below the limit of detection for the majority of samples and therefore were not analyzed.

Discussion

In this piglet mode of inflammation-sensitized HI, we did not observe protection with 24h HT (from 1–25h after HI) based on pre-defined primary outcome measures; aEEG, MRS and histological cell death (TUNEL positive cells). Microglial activation and glial cell proliferation were unaltered, although microglial activation was increased in the caudate nucleus with HT. Compared to normothermia, HT suppressed the platelet and white cell count response. Plasma and CSF cytokine response to LPS and HI was largely unchanged with HT. HT reduced CC3 throughout the brain; in our model, CC3 is a poor marker of cell death (30) and in this and previous studies, a regional reduction in CC3 is associated with increased TUNEL positive cells.

These results differ to non-sensitized HI piglet models, where HT for 24h started at 2h after HI reduced brain injury based on TUNEL positive cell counts (17) and HT for 12-24h started immediately after HI ameliorated secondary energy failure, reduced seizure activity and improved neurological functional and histopathology scores (31, 32). In the present study, a trend towards increased TUNEL positive cell death in the internal capsule with HT was observed. Concurring with the histological data, aEEG and ^{1}H MRS were not improved by HT. Comparing NT and HT groups, there was no difference in aEEG score or seizure burden. The mean aEEG score for HT trended upwards from 31 h; this may be attributed to loss of two subjects who had flat traces (score 0). In NE babies, a recovery of aEEG within 48h is associated with a good outcome (33). ^{1}H MRS Lac/NAA peak area ratios in the white matter and thalamus were not improved by HT. In nonsensitized piglet models, HT for 24h improves MRS biomarkers, including Lac/NAA (31, 34, 35) which is a robust marker of 2 year neurodevelopmental outcome in NE babies (36).

Suppression of microglial activity is a favorable marker (7) and key mechanism by which HT is neuroprotective (37, 38). Reduced microglial activation following HT is observed in non-sensitized HI models, including the pig (17), sheep (38) and rodent (39). In this

IS-HI model, microglial number and morphology were not suppressed by HT; indeed, in the caudate nucleus, microglial morphology was indicative of a pro-inflammatory activation state with HT, possibly reflecting increased injury. Our findings concur with those from a rodent LPS-sensitized HI cooling model (40). The balance between activated microglia with a pro-inflammatory phenotype and those with an anti-inflammatory restorative phenotype is complex and needs further study (7, 12, 41). Astrogliosis, measured by GFAP, was not impacted by HT. In non-sensitized HI models, HT reduces astroglial activation (39). LPS enhances astrogliosis by stimulating release of TNFα, IL-1α and IL-6, mediators of astrocyte proliferation and activation (42, 43). A failure of HT to suppress astrogliosis has also been shown in an LPS-sensitized rodent model (40).

CC3 was reduced by HT, both overall and specifically in the internal capsule, caudate nucleus and hippocampus. As in our previous LPS + Hypoxia study (10) and other recent piglet neuroprotection studies (44, 45), CC3 was not associated with TUNEL positive cell death. The use of male piglets may partly explain these data; cell death is sexually dimorphic and in males, cell death pathways are predominantly caspase-independent (46–48). We may then conclude that CC3 is therefore a poor marker of cell death in this model. LPS is known to increase CC3 without resulting in apoptotic cell death (10, 49). This CC3 response to LPS likely reflects the immunologic functions of caspases, including microglial and lymphocyte function, cell differentiation and autophagy (50). Of note, the largest reduction in CC3 with HT was observed in the internal capsule, the same region where there was a trend towards an increase in TUNEL positive cell death.

HI, HT and LPS each influence the hematological response. Infection/inflammation triggers thrombocytopenia and leucocytosis in neonates (51) and piglets (10). HI also stimulates leucocytosis (10, 52). HT is known to reduce circulating platelets and WBC. A meta-analysis of HT clinical trials demonstrated an increase in thrombocytopenia (relative risk (RR) 1.21 (95% CI 1.05 - 1.40) with HT, and an increase in leucopenia with whole body HT (RR 5.7 (95% CI 1.02 — 31.82) (1). Similarly, in this study, HT suppressed both platelet and leucocyte (neutrophil) count. The impact of this suppression is uncertain in the setting of IS-HI. In a mouse model of LPS-sensitised HI, neutrophils were central to injury pathways, leading to leucocyte infiltration, pro-inflammatory cytokine production and brain atrophy (53). By contrast, an increase in circulating neutrophils, and later lymphocytes, are necessary components of the innate and adaptive immune response to infectious stimuli. Leucopenic 'immune paralysis' has been demonstrated in neonates undergoing HT and was associated with poorer outcome (16). Thus, alterations in immune cell number may be an important factor in the efficacy and safety of TH in IS-HI.

Many immune cells are functionally heat-sensitive (54) and a key mechanism of HT neuroprotection is inhibition of the pro-inflammatory cascade (18, 55, 56). In a cohort of babies with NE, HT infants had reduced serum IL-6 and IL-4, and increased VEGF compared with NT infants (57). In the same cohort, there was a negative correlation between the duration of cooling prior to sampling, and levels of IL-6, IL-10, TNFα and interferon-gamma (IFNγ) (57). In another cohort, HT lowered IL-6, and increased IL-10 at 48h (58). Conversely, in a phase II cooling trial, cooled infants had a biphasic pattern of elevated IL-6, IL-8, IL-10 and chemokine (C-C motif) ligand 2 in comparison with NT

infants (18) although another prospective cohort showed serial cytokine values (IL-1, IL-6, IL-8, TNFα, IFNγ, and VEGF) were unaffected by HT (59). In our study, plasma and CSF cytokine profiles were not influenced by HT. IL-6, IL-8 and TNFα increased from baseline in response to LPS. IL-6 was higher at 3h post HI in HT compared to NT. The inability of HT to suppress pro-inflammatory cytokine production in IS-HI may contribute to the lack of cooling effect. Indeed, in one cooling cohort, neonates that failed to down-modulate pro-inflammatory cytokines in response to HT had poorer outcome (18).

Mortality in HT was 33% (2 deaths), compared with no deaths in NT. Neonates with both infection/inflammation and an intrapartum hypoxic event are at increased risk of mortality; in a large meta-analysis of cooled and non-cooled infants, mortality amongst infants with both Group B Streptococcus sepsis and NE was higher than for infants with NE alone (RR 2.07 (95% CI 1.47-2.91)) (13). In our previous normothermic piglet study, the combination of LPS + Hypoxia increased mortality compared with hypoxia alone (10). In this study, the two cardiac arrests were preceded by refractory hypotension, which may have been contributed to by HT-induced bradycardia. Indeed, in a meta-analysis of cooling trials, HT increased sinus bradycardia although there was no increase in hypotension or major arrhythmias (1). The HT group was hyperglycemic during the cooling phase. HT reduces insulin secretion and increases insulin resistance in preclinical models and adult HT studies (60). Deranged postnatal glycemic control is an important risk factor for adverse outcome as seen in the Coolcap study (61) and is associated with specific patterns of brain injury in NE (62). Two piglets in the HT group had macroscopic abdominal organ necrosis, including the bowel, at postmortem.

There are limitations to this study. By using E. *coli* LPS to stimulate inflammation, we modelled only gram-negative perinatal infection. Rodent models of IS-HI comparing LPS with PAM3CSK4 (a toll-like receptor (TLR) 2 agonist which simulates gram-positive infection) demonstrate differences in temperature, cytokine expression, CC3 and glial cell response (40). Importantly, efficacy of HT was pathogen dependent; HT was neuroprotective in PAM3CSK4 IS-HI, but not with LPS IS-HI (14, 15, 25). Two of six piglets in the HT group were rewarmed early due to refractory hypotension, consistent with clinical practice. These two piglets died prematurely, reducing the available outcome data at later time points. With reduced numbers the study may have been underpowered to demonstrate differences in later outcome measures, including aEEG and MRS. Histological outcomes measures were available for all 12 subjects, including the 2 piglets that died prematurely. Only male piglets were used to reduce intergroup variation. We were therefore not able to examine the impact of sex on outcome (46). Future studies using this model of IS-HI will be conducted using both male and female piglets. The porcine immune system is an ideal model for immunology research, resembling human by >80%. However, there are differences, for example, piglets are born without transplacental antibodies in contrast to human neonates (63). This impacts interpretation of the immunomodulatory effects of HT. The insult in this study was a combined carotid artery occlusion with hypoxia rather than a pure hypoxia model where we observed significant systemic injury (10).

HT was undertaken for 24h (from 1-25h) in the present study, a duration that is protective in our non-sensitized piglet HI model (when HT commencement was delayed to 2h) (17)

and allows time for gradual rewarming and subsequent neuroimaging under normothermic conditions within the timeframe of our established 48h model (64, 65). HT maintained for 24h is neuroprotective in rodent and porcine models of non-sensitized HI (17, 31, 32). The closer to HI that HT is commenced in these models, the greater the neuroprotection and the shorter the duration of cooling required (37). However, optimal cooling duration, based on preclinical (66, 67) and clinical studies (68), is 72 h. In the fetal lamb, 72h HT (from 3-75h) provided maximal neuroprotection following HI compared with either 48h or 120h HT, with regards EEG and histological outcome measures (66, 69), with the rate of rewarming of lesser importance (70). Thus we cannot exclude the possibility of a different effect of 72h versus 24h cooling in IS-HI.

In this IS-HI model, both LPS and HI stimulate systemic multi-organ inflammatory responses and injury. Plasma cytokines were 1-2 orders of magnitude higher than CSF cytokines suggesting predominant peripheral immune cell response in this model. HT effects on the peripheral immune response may have impacted upon brain injury. Whole body cooling was undertaken in this study, consistent with clinical care. Selective head cooling may have a differential effect to whole body cooling, through avoidance of systemic HT immunomodulation.

Our results, suggesting no protection with HT in IS-HI, may be related to: i. Failure of HT to inhibit microglial activation, astrogliosis and inflammatory cytokine production; ii. Attenuation of neutrophil numbers by HT; iii. Secondary brain injury from hemodynamic instability; and iv. Abnormal glycaemic control. Following HI, HT inhibits both protective and damaging cellular pathways; in IS-HI, the balance of inhibition may be detrimental. Given the dual role of the immune response in both contributing to and preventing injury, and the complex mechanisms underpinning evolution of HI injury, therapies targeting immunomodulation, rather than inflammation suppression require exploration (7, 71).

Novel neuroprotective therapies require exploration in IS-HI models. In experimental rodent models of IS-HI, promising therapies include melatonin (72), N-acetylcysteine (73), hydrocortisone (74), and inflammatory cascade inhibitors/antagonists of IL-1 receptor (75), nuclear factor kappa beta (76), plasminogen activator protein-1 (77) and histone deacetylase (78). Other possible therapies include erythropoietin (79, 80), mesenchymal stem cells (MSCs) (81), TLR modulators (71, 82), cyclooxygenase-2 inhibitors (83) and immunomodulatory antibiotics such as azithromycin (84) and minocycline (85). It will be important to assess therapies with and without HT; of concern is the negated benefit, or even exacerbation of injury, observed with therapies such as IL-1 receptor antagonists (86) and MSCs (87) when combined with HT.

Unlike the protection seen previously with 24h HT (from 2-26h) in the piglet HI model (17), we did not observe protection with 24h HT (from 1-25h) in a model of IS-HI. Our observation was based on EEG, MRS and TUNEL positive cell death. The reduced efficacy of HT in the context of IS-HI, may relate to the inability of HT to alter glial cell function and pro-inflammatory cytokine profile as well as systemic effects of hyperglycemia and hemodynamic instability. Hypothermic suppression of leucocytes, platelets and CC3

may be detrimental in systemic inflammatory illness. Novel neuroprotective agents with immunomodulatory properties require exploration in IS-HI models.

Acknowledgments

References

1. Jacobs S, et al. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst Rev. 2013.

2. Shankaran S, et al. Childhood outcomes after hypothermia for neonatal encephalopathy. N Engl J Med. 2012; 366: 2085–2092. [PubMed: 22646631]

3. Jary S, Smit E, Liu X, Cowan FM, Thoresen M. Less severe cerebral palsy outcomes in infants treated with therapeutic hypothermia. Acta Paediatr. 2015; 104: 1241–1247. [PubMed: 26237284]

4. Lee-Kelland R, et al. School-age outcomes of children without cerebral palsy cooled for neonatal hypoxic-ischaemic encephalopathy in 2008-2010. Arch Dis Child Fetal Neonatal Ed. 2020; 105: 8–13. [PubMed: 31036702]

5. Badawi N, et al. Antepartum risk factors for newborn encephalopathy: the Western Australian case-control study. BMJ. 1998; 317: 1549–1553. [PubMed: 9836652]

6. MacLennan AH, Thompson SC, Gecz J. Cerebral palsy: causes, pathways, and the role of genetic variants. Am J Obstet Gynecol. 2015; 213: 779–788. [PubMed: 26003063]

7. Hagberg H, et al. The role of inflammation in perinatal brain injury. Nat Rev Neurol. 2015; 11: 192–208. [PubMed: 25686754]

8. Nelson KB, et al. Antecedents of neonatal encephalopathy in the Vermont Oxford Network Encephalopathy Registry. Pediatrics. 2012; 130: 878–886. [PubMed: 23071210]

9. Eklind S, et al. Bacterial endotoxin sensitizes the immature brain to hypoxic-ischaemia injury. Eur J Neurosci. 2001; 13: 1101–1106. [PubMed: 11285007]

10. Martinello KA, et al. Acute LPS sensitization and continuous infusion exacerbates hypoxic brain injury in a piglet model of neonatal encephalopathy. Sci Rep. 2019; 9 10184 [PubMed: 31308390]

11. Nelson KB, Penn AA. Is infection a factor in neonatal encephalopathy? Arch Dis Child Fetal Neonatal Ed. 2015; 100: F8–F10. [PubMed: 25169244]

12. Bhalala US, Koehler RC, Kannan S. Neuroinflammation and neuroimmune dysregulation after acute hypoxic-ischemic injury of developing brain. Front Pediatr. 2014; 2: 144. [PubMed: 25642419]

13. Tann CJ, et al. Neonatal Encephalopathy With Group B Streptococcal Disease Worldwide: Systematic Review, Investigator Group Datasets, and Meta-analysis. Clin Infect Dis. 2017; 65: S173–S189. [PubMed: 29117330]

14. Osredkar D, et al. Hypothermia is not neuroprotective after infection-sensitized neonatal hypoxic-ischemic brain injury. Resuscitation. 2014; 85: 567–572. [PubMed: 24361672]

15. Falck M, et al. Hypothermic Neuronal Rescue from Infection-Sensitised Hypoxic-Ischaemic Brain Injury Is Pathogen Dependent. Dev Neurosci. 2017.

16. Jenkins DD, et al. Altered circulating leukocytes and their chemokines in a clinical trial of therapeutic hypothermia for neonatal hypoxic ischemic encephalopathy. Pediatr Crit Care Med. 2013; 14: 786–795. [PubMed: 23897243]

17. Alonso-Alconada D, et al. Brain cell death is reduced with cooling by 3.5 degrees C to 5 degrees C but increased with cooling by 8.5 degrees C in a piglet asphyxia model. Stroke. 2015; 46: 275–278. [PubMed: 25424475]

18. Jenkins DD, et al. Serum cytokines in a clinical trial of hypothermia for neonatal hypoxic-ischemic encephalopathy. J Cereb Blood Flow Metab. 2012; 32: 1888–1896. [PubMed: 22805873]

19. Armstrong K, Franklin O, Sweetman D, Molloy EJ. Cardiovascular dysfunction in infants with neonatal encephalopathy. Arch Dis Child. 2012; 97: 372–375. [PubMed: 21798875]

20. Wintermark P, Boyd T, Gregas MC, Labrecque M, Hansen A. Placental pathology in asphyxiated newborns meeting the criteria for therapeutic hypothermia. Am J Obstet Gynecol. 2010; 203: 579. e571-579 [PubMed: 20851370]

21. Pauliah SS, Shankaran S, Wade A, Cady EB, Thayyil S. Therapeutic hypothermia for neonatal encephalopathy in low- and middle-income countries: a systematic review and meta-analysis. PLoS One. 2013; 8 e58834 [PubMed: 23527034]

22. Robertson NJ, et al. Therapeutic hypothermia for birth asphyxia in low-resource settings: a pilot randomised controlled trial. Lancet. 2008; 372: 801–803. [PubMed: 18774411]

23. Mourvillier B, et al. Induced hypothermia in severe bacterial meningitis: a randomized clinical trial. JAMA. 2013; 310: 2174–2183. [PubMed: 24105303]

24. Itenov TS, et al. Induced hypothermia in patients with septic shock and respiratory failure (CASS): a randomised, controlled, open-label trial. Lancet Respir Med. 2018; 6: 183–192. [PubMed: 29325753]

25. Falck M, et al. Hypothermia Is Neuroprotective after Severe Hypoxic-Ischaemic Brain Injury in Neonatal Rats Pre-Exposed to PAM3CSK4. Dev Neurosci. 2018. 1–9.

26. Azzopardi D, et al. Prognosis of newborn infants with hypoxic-ischemic brain injury assessed by phosphorus magnetic resonance spectroscopy. Pediatr Res. 1989; 25: 445–451. [PubMed: 2717259]

27. Lorek A, et al. Delayed ("secondary") cerebral energy failure after acute hypoxiaischemia in the newborn piglet: continuous 48-hour studies by phosphorus magnetic resonance spectroscopy. Pediatr Res. 1994; 36: 699–706. [PubMed: 7898977]

28. de Vries LS, Hellstrom-Westas L. Role of cerebral function monitoring in the newborn. Arch Dis Child Fetal Neonatal Ed. 2005; 90: F201–207. [PubMed: 15846008]

29. Wilson M, Reynolds G, Kauppinen RA, Arvanitis TN, Peet AC. A constrained least-squares approach to the automated quantitation of in vivo (1)H magnetic resonance spectroscopy data. Magn Reson Med. 2011; 65: 1–12. [PubMed: 20878762]

30. Pang R, et al. Proton Magnetic Resonance Spectroscopy Lactate/N-Acetylaspartate Within 48 h Predicts Cell Death Following Varied Neuroprotective Interventions in a Piglet Model of Hypoxia–Ischemia With and Without Inflammation-Sensitization. Front Neurol. 2020; 11

31. Thoresen M, et al. Mild Hypothermia after Severe Transient Hypoxia-Ischemia Ameliorates Delayed Cerebral Energy Failure in the Newborn Piglet. Pediatr Res. 1995; 37: 667–670. [PubMed: 7603788]

32. Tooley JR, Satas S, Porter H, Silver IA, Thoresen M. Head cooling with mild systemic hypothermia in anesthetized piglets is neuroprotective. Ann Neurol. 2003; 53: 65–72. [PubMed: 12509849]

33. Thoresen M, Hellstrom-Westas L, Liu X, de Vries LS. Effect of hypothermia on amplitude-integrated electroencephalogram in infants with asphyxia. Pediatrics. 2010; 126: e131–139. [PubMed: 20566612]

34. Huun MU, et al. DHA and therapeutic hypothermia in a short-term follow-up piglet model of hypoxia-ischemia: Effects on H+MRS biomarkers. PLoS One. 2018; 13 e0201895 [PubMed: 30086156]

35. Rocha-Ferreira E, et al. Systemic pro-inflammatory cytokine status following therapeutic hypothermia in a piglet hypoxia-ischemia model. J Neuroinflammation. 2017; 14: 44. [PubMed: 28253907]

36. Mitra S, et al. Proton magnetic resonance spectroscopy lactate/N-acetylaspartate within 2 weeks of birth accurately predicts 2-year motor, cognitive and language outcomes in neonatal encephalopathy after therapeutic hypothermia. Arch Dis Child Fetal Neonatal Ed. 2018.

37. Gunn AJ, et al. Therapeutic hypothermia translates from ancient history in to practice. Pediatr Res. 2017; 81: 202–209. [PubMed: 27673420]

38. Wassink G, Gunn ER, Drury PP, Bennet L, Gunn AJ. The mechanisms and treatment of asphyxial encephalopathy. Front Neurosci. 2014; 8: 40. [PubMed: 24578682]

39. Rocha-Ferreira E, Vincent A, Bright S, Peebles DM, Hristova M. The duration of hypothermia affects short-term neuroprotection in a mouse model of neonatal hypoxic ischaemic injury. PLoS One. 2018; 13 e0199890 [PubMed: 29969470]

40. Osredkar D, et al. Hypothermia Does Not Reverse Cellular Responses Caused by Lipopolysaccharide in Neonatal Hypoxic-Ischaemic Brain Injury. Dev Neurosci. 2015; 37: 390–397. [PubMed: 26087775]

41. Chhor V, et al. Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain BehavImmun. 2013; 32: 70–85.

42. Girard S, et al. Postnatal administration of IL-1Ra exerts neuroprotective effects following perinatal inflammation and/or hypoxic-ischemic injuries. Brain Behav Immun. 2012; 26: 1331–1339. [PubMed: 22982341]

43. Selmaj KW, Farooq M, Norton WT, Raine CS, Brosnan CF. Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. J Immunol. 1990; 144: 129–135. [PubMed: 2104886]

44. Lingam I, et al. Short-term effects of early initiation of magnesium infusion combined with cooling after hypoxia-ischemia in term piglets. PediatrRes. 2019.

45. Robertson NJ, et al. Melatonin as an adjunct to therapeutic hypothermia in a piglet model of neonatal encephalopathy: A translational study. Neurobiol Dis. 2018.

46. Charriaut-Marlangue C, Besson VC, Baud O. Sexually Dimorphic Outcomes after Neonatal Stroke and Hypoxia-Ischemia. Int J Mol Sci. 2017; 19

47. Zhu C, et al. Different apoptotic mechanisms are activated in male and female brains after neonatal hypoxia-ischaemia. J Neurochem. 2006; 96: 1016–1027. [PubMed: 16412092]

48. Hagberg H, et al. PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury. J Neurochem. 2004; 90: 1068–1075. [PubMed: 15312162]

49. Burguillos MA, et al. Caspase signalling controls microglia activation and neurotoxicity. Nature. 2011; 472: 319–324. [PubMed: 21389984]

50. Abraham MC, Shaham S. Death without caspases, caspases without death. Trends Cell Biol. 2004; 14: 184–193. [PubMed: 15066636]

51. Sola-Visner M, Sallmon H, Brown R. New insights in the mechansims of non-immune thrombocytopenia in neonates. Semin Perinatol. 2009; 33: 43–51. [PubMed: 19167581]

52. Koreti S, Eske GS, Gaur A, Gupta A. Study of hematological parameters among newborns with perinatal asphyxia. Ped Rev: Int J Ped Rev. 2018; 5

53. Yao H-W, Kuan C-Y. Early neutrophil depletion reduces inflammation-sensitized hypoxic-ischemic brain injury in mouse neonates. J Immunol. 2018; 200: 102–110.

54. Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat. Nat Rev Immunol. 2015; 15: 335–349. [PubMed: 25976513]

55. Kimura A, Sakurada S, Ohkuni H, Todome Y, Kurata K. Moderate hypothermia delays proinflammatory cytokine production of human peripheral blood mononuclear cells. Crit Care Med. 2002; 30: 1499–1502. [PubMed: 12130969]

56. Nakamura T, Yamada S, Yoshioka T. Brain hypothermic therapy dramatically decreases elevated blood concentrations of high mobility group box 1 in neonates with hypoxic-ischemic encephalopathy. Dis Markers. 2013; 35: 327–330. [PubMed: 24191125]

57. Roka A, et al. Changes in serum cytokine and cortisol levels in normothermic and hypothermic term neonates after perinatal asphyxia. Inflamm Res. 2013; 62: 81–87. [PubMed: 22986466]

58. Moon CJ, Youn YA, Yum SK, Sung IK. Cytokine changes in newborns with therapeutic hypothermia after hypoxic ischemic encephalopathy. J Perinatol. 2016; 36: 1092–1096. [PubMed: 27583390]

59. Chalak LF, et al. Biomarkers for severity of neonatal hypoxic-ischemic encephalopathy and outcomes in newborns receiving hypothermia therapy. J Pediatr. 2014; 164: 468–474. e461 [PubMed: 24332821]

60. Haase KK, Grelle JL, Khasawneh FA, Ike C. Variability in Glycemic Control with Temperature Transitions during Therapeutic Hypothermia. Crit Care Res Pract. 2017; 2017 4831480 [PubMed: 29075530]

61. Basu SK, et al. Hypoglycaemia and hyperglycaemia are associated with unfavourable outcome in infants with hypoxic ischaemic encephalopathy: a post hoc analysis of the CoolCap Study. Arch Dis Child Fetal Neonatal Ed. 2015.

62. Basu SK, et al. Early Glycemic Profile Is Associated with Brain Injury Patterns on Magnetic Resonance Imaging in Hypoxic Ischemic Encephalopathy. J Pediatr. 2018; 203: 137–143. [PubMed: 30197201]

63. Pabst R. The pig as a model for immunology research. Cell Tissue Res. 2020; 380: 287–304. [PubMed: 32356014]

64. Robertson NJ, et al. Melatonin as an adjunct to therapeutic hypothermia in a piglet model of neonatal encephalopathy: A translational study. Neurobiol Dis. 2019; 121: 240–251. [PubMed: 30300675]

65. Robertson NJ, et al. High-Dose Melatonin and Ethanol Excipient Combined with Therapeutic Hypothermia in a Newborn Piglet Asphyxia Model. Sci Rep. 2020; 10: 3898. [PubMed: 32127612]

66. Davidson JO, et al. How long is too long for cerebral cooling after ischemia in fetal sheep? J Cereb Blood Flow Metab. 2015; 35: 751–758. [PubMed: 25605291]

67. Davidson JO, et al. Extending the duration of hypothermia does not further improve white matter protection after ischemia in term-equivalent fetal sheep. Sci Rep. 2016; 6 25178 [PubMed: 27121655]

68. Shankaran S, et al. Effect of Depth and Duration of Cooling on Death or Disability at Age 18 Months Among Neonates With Hypoxic-Ischemic Encephalopathy: A Randomized Clinical Trial. JAMA. 2017; 318: 57–67. [PubMed: 28672318]

69. Davidson JO, et al. How long is sufficient for optimal neuroprotection with cerebral cooling after ischemia in fetal sheep? J Cereb Blood Flow Metab. 2018; 38: 1047–1059. [PubMed: 28504050]

70. Davidson JO, et al. Limited benefit of slow rewarming after cerebral hypothermia for global cerebral ischemia in near-term fetal sheep. J Cereb Blood Flow Metab. 2018. 271678X18791631

71. Cho KH, Davidson JO, Dean JM, Bennet L, Gunn AJ. Cooling and immunomodulation for treating hypoxic-ischemic brain injury. Pediatr Int. 2020; 62: 770–778. [PubMed: 32119180]

72. Wang X, et al. Melatonin and N-acetylcysteine reduce brain injury in response to lipopolysaccharide-sensitized hypoxia-ischemia. Am J Obstet Gynecol. 2005; 193 S28

73. Wang X, et al. N-acetylcysteine reduces lipopolysaccharide-sensitized hypoxic-ischemic brain injury. Ann Neurol. 2007; 61: 263–271. [PubMed: 17253623]

74. Harding B, Conception K, Li Y, Zhang L. Glucocorticoids Protect Neonatal Rat Brain in Model of Hypoxic-Ischemic Encephalopathy (HIE). Int J Mol Sci. 2016; 18

75. Savard A, et al. Neuronal self-injury mediated by IL-1beta and MMP-9 in a cerebral palsy model of severe neonatal encephalopathy induced by immune activation plus hypoxia-ischemia. J Neuroinflammation. 2015; 12: 111. [PubMed: 26025257]

76. Yang D, et al. Intranasal delivery of cell-penetrating anti-NF-κB peptides (Tat-NBD) alleviates infection-sensitized hypoxic-ischemic brain injury. Exp Neurol. 2013; 247: 447–455. [PubMed: 23353638]

77. Yang D, et al. Plasminogen activator inhibitor-1 mitigates brain injury in a rat model of infection-sensitized neonatal hypoxia-ischemia. Cereb Cortex. 2013; 23: 1218–1229. [PubMed: 22556277]

78. Fleiss B, Nilsson MK, Blomgren K, Mallard C. Neuroprotection by the histone deacetylase inhibitor trichostatin A in a model of lipopolysaccharide-sensitised neonatal hypoxic-ischaemic brain injury. J Neuroinflammation. 2012; 9: 70. [PubMed: 22512781]

79. Xu FL, et al. Effects of erythropoietin on neuronal proliferation and apoptosis in neonatal rats after infection-induced brain injury. Zhongguo Dang Dai Er Ke Za Zhi. 2014; 16: 290–294. [PubMed: 24661524]

80. Traudt CM, et al. Concurrent erythropoietin and hypothermia treatment improve outcomes in a term nonhuman primate model of perinatal asphyxia. Dev Neurosci. 2013; 35: 491–503. [PubMed: 24192275]

81. Wagenaar N, Nijboer CH, van Bel F. Repair of neonatal brain injury: bringing stem cell-based therapy into clinical practice. Dev Med Child Neurol. 2017; 59: 997–1003. [PubMed: 28786482]

82. Cho KHT, et al. Protective effects of delayed intraventricular TLR7 agonist administration on cerebral white and gray matter following asphyxia in the preterm fetal sheep. Sci Rep. 2019; 9: 9562. [PubMed: 31267031]

83. Shiow LR, et al. Reactive astrocyte COX2-PGE2 production inhibits oligodendrocyte maturation in neonatal white matter injury. Glia. 2017; 65: 2024–2037. [PubMed: 28856805]

84. Barks JDE, Liu Y, Wang L, Pai MP, Silverstein FS. Repurposing azithromycin for neonatal neuroprotection. Pediatr Res. 2019; 86: 444–451. [PubMed: 31100754]

85. Buller KM, Carty ML, Reinebrant HE, Wixey JA. Minocycline: a neuroprotective agent for hypoxic-ischemic brain injury in the neonate? J Neurosci Res. 2009; 87: 599–608. [PubMed: 18831005]

86. Chevin M, Guiraut C, Sébire G. Effect of hypothermia on interleukin-1 receptor antagonist pharmacodynamics in inflammatory-sensitized hypoxic-ischemic encephalopathy of term newborns. J Neuroinflammation. 2018; 15: 214. [PubMed: 30060742]

87. Herz J, et al. Interaction between hypothermia and delayed mesenchymal stem cell therapy in neonatal hypoxic-ischemic brain injury. Brain Behav Immun. 2018; 70: 118–130. [PubMed: 29454023]

Impact Statement

- Acute infection/inflammation is known to exacerbate perinatal brain injury and worsen outcome in neonatal encephalopathy

- Therapeutic hypothermia is the current standard of care for all infants with NE but the benefit in infants with co-infection/inflammation is unknown

- In a piglet model of inflammation (LPS) sensitized hypoxia ischemia we observed no evidence of neuroprotection with cooling for 24h, based on our primary outcome measures: aEEG, MRS Lac/NAA and histological brain cell death

- Additional neuroprotective agents, with beneficial immunomodulatory effects, require exploration in inflammation-sensitized hypoxic-ischemic models

Figure 1.
Study timeline. Following baseline recordings and surgery, piglets received a 2µg/kg LPS bolus, followed by 1µg/kg/h *E. Coli* LPS infusion continued for 52h. After 4h of infusion, piglets underwent a transient hypoxic ischemic (HI) insult. Animals were subsequently randomized to i) Normothermia (NT, core 38.0-39.0°C throughout), or ii) Hypothermia (HT, 33.5°C from 1-25h post HI, then rewarmed at 0.5°C /h). Blood samples were collected at baseline, 4h after bolus, end HI (time 0), and at 3, 12, 24 and 48h after HI. EEG was continuously acquired, excluding during MRS at 24 and 48h. Piglets were maintained under meticulous intensive care for 48h following HI, prior to euthanasia and histological specimen collection.

Figure 2.
A. TUNEL histology. There was no difference between whole brain or regional estimated least square mean (LSM) TUNEL positive cells per mm^2; B. LSM whole brain and regional cleaved caspase 3 (CC3), GFAP, IBA1 positive cell count and IBA1 ramification index. Hypothermia reduced CC3 throughout the brain and in the internal capsule, caudate nucleus and hippocampus. Hypothermia did not alter astrogliosis. Cooling had no effect on overall microglial number or activation state. There was an increase in microglial activation (lower ramification index) in the caudate with HT; C. Representative sections

for each stain (TUNEL, CC3, GFAP and IBA1) from the internal capsule are shown at ×40 magnification. Cingulate cortex = cCTX; Sensorimotor cortex = sCTX; Hippocampus = HIP; Periventricular white matter = PvWM; Internal capsule = IC; Caudate = CAUD; Putamen = PTMN; Thalamus = THAL. Data displayed as analyzed, on a log10 scale. Error bars represent 95% CI

Figure 3.
Mean aEEG pattern classification score from baseline (BL) till 48h, divided into 6h time epochs (A) (+/- 95% CI). There was no difference between NT and HT aEEG score at any time. The 2 crosses represent the deaths of 2 HT piglets at 30h and 33h. Examples of each pattern classification score are shown (B), where 0=flat trace, 1=low voltage, 2=burst suppression, 3=discontinuous normal voltage and 4=continuous normal voltage.

Figure 4.
MRS. There is no effect of hypothermia on the ratio of Lactate to N-acetyl aspartate (Lac/NAA) in the thalamus or white matter at 24 or 48h after HI. All subjects log10 Lac/NAA data points are shown in the graphs on the left/centre, and are summarized using log10 least squares (LS) means plot with 95% CI error bars in the boxes on the right. The crosses indicate the 2 HT piglets who died prior to the 48h scan.

Figure 5.
Least square (LS) mean values over time for platelets, white blood cells (WBC), neutrophils, lymphocytes, monocyte counts and hemoglobin (+/- SEM). Pale blue shading represents cooling. * p<0.05, ** p<0.01, *** p<0.0001 for change from baseline value, with color denoting group; # p<0.05 for difference at time point between NT and HT group

Figure 6.
Mean values over time for IL-6, IL-8 and TNFα in the plasma and cerebrospinal fluid (CSF) (+/- SEM). Pale blue shading represents cooling. * p<0.05 difference at time point between NT and HT group

Table 1

Physiological observations and blood gas results throughout the experiment

		Normothermia		Hypothermia	
		Mean	(SD)	Mean	(SD)
Weight (g)		2008	(132)	2075	(161)
Rectal Temp (°C)	Baseline	37.9	(0.8)	37.6	(0.4)
	4h LPS	38.6	(0.3)	38.6	(0.3)
	End of insult	38.1	(0.5)	38.1	(0.3)
	1-25h	38.4	(0.1)	34.0	(0.5)**
	25-35h	38.7	(0.1)	36.5	(1.3)**
	35-48h	38.4	(0.2)	38.2	(0.2)
Heart Rate (bpm)	Baseline	169.1	(26.0)	151.7	(11.9)
	4h LPS	192.9	(15.0)	185.0	(12.6)
	End of insult	237.3	(15.8)	225.6	(12.9)
	1-25h	234.9	(20.5)	170.9	(24.8)**
	25-35h	210.0	(25.2)	180.0	(8.7)*
	35-48h	185.2	(21.7)	173.0	(13.1)
MABP (mmHg)	Baseline	51.1	(4.3)	52.1	(1.4)
	4h LPS	53.1	(3.7)	54.1	(5.8)
	End of insult	47.3	(6.3)	43.7	(5.6)
	1-25h	45.7	(5.4)	42.7	(9.8)
	25-35h	55.0	(5.2)	42.8	(15.0)
	35-48h	49.5	(2.9)	54.8	(4.5)
pH	Baseline	7.48	(0.19)	7.57	(0.10)
	4h LPS	7.44	(0.10)	7.45	(0.07)
	End of insult	7.22	(0.11)	7.25	(0.13)
	12h	7.49	(0.07)	7.44	(0.17)
	24h	7.47	(0.03)	7.38	(0.13)
	48h	7.47	(0.04)	7.48	(0.05)
PaC02 (kPa)	Baseline	6.3	(3.4)	4.3	(0.8)
	4h LPS	5.8	(1.0)	5.6	(0.7)
	End of insult	6.3	(1.8)	5.6	(0.9)
	12h	5.3	(0.6)	4.4	(1.1)
	24h	5.4	(0.7)	5.1	(1.3)
	48h	5.2	(0.6)	5.0	(0.4)
PaO2 (kPa)	Baseline	18.6	(2.7)	15.0	(4.3)
	4h LPS	10.4	(1.1)	10.8	(0.9)
	End of insult	3.6	(0.4)	3.7	(0.9)
	12h	13.7	(4.8)	15.5	(6.6)

		Normothermia		Hypothermia	
		Mean	**(SD)**	**Mean**	**(SD)**
	24h	12.8	(3.1)	10.7	(4.0)
	48h	15.2	(3.9)	14.6	(1.8)
BE (mmol/L)	Baseline	8.5	(3.3)	7.7	(4.4)
	4h LPS	5.9	(3.4)	5.1	(3.4)
	End of insult	-9.0	(2.9)	-8.7	(4.9)
	12h	6.8	(3.4)	-0.3	(10.5)
	24h	5.7	(2.1)	-1.7	(9.8)
	48h	4.5	(2.4)	5.4	(4.9)
Lactate (mmol/L)	Baseline	3.6	(1.7)	2.9	(1.2)
	4h LPS	4.1	(2.0)	3.4	(1.3)
	End of insult	13.1	(1.7)	11.0	(2.2)
	12h	3.0	(0.6)	6.6	(5.0)
	24h	2.3	(0.8)	6.7	(7.1)
	48h	1.1	(0.2)	1.3	(0.3)
Glucose (mmol/L)	Baseline	4.9	(1.3)	5.2	(1.2)
	4h LPS	6.0	(2.2)	5.6	(0.5)
	End of insult	8.9	(3.0)	7.9	(1.0)
	12h	6.8	(1.2)	11.5	(5.6)
	24h	6.5	(1.2)	10.3	(3.6)[*]
	48h	4.5	(1.2)	4.9	(0.7)
Potassium (mmol/L)	Baseline	4.1	(0.7)	4.5	(0.4)
	4h LPS	4.5	(0.4)	5.0	(0.4)
	End of insult	4.5	(0.5)	5.2	(0.8)
	12h	6.3	(0.7)	6.3	(1.0)
	24h	6.7	(0.7)	6.7	(1.4)
	48h	5.7	(1.2)	6.2	(1.3)

MABP mean arterial blood pressure, *BE* base excess

[*]
p<0.05

[**]
p<0.005

Table 2

Hypoxic ischemic insult severity measures

	Normothermia		Hypothermia	
	Mean	**(SD)**	**Mean**	**(SD)**
Duration HI (min)	20.7	(1.4)	21.2	(2.1)
AUC FiO2 (%)	295.8	(20.1)	290.5	(43.2)
Duration of EEG <5μ.V (min)	15.5	(2.9)	17.7	(1.8)
Duration of MABP < 30 (min)	7.3	(2.9)	10.0	(3.8)
AUC oxCCO	146	(25)	124	(50)
End of HI arterial gas:				
pH	7.22	(0.11)	7.25	(0.13)
pCO2 (kPa)	6.3	(1.8)	5.6	(0.9)
pO2 (kPa)	3.6	(0.4)	3.7	(0.9)
Base excess	-9.0	(2.9)	-8.7	(4.9)
Lactate (mmol/L)	13.1	(1.7)	11.0	(2.2)

HI hypoxia ischemia, *EEG* electroencephalogram, *MABP* mean arterial blood pressure, *oxCCO* oxidized cytochrome C oxidase
No comparisons were p<0.05

Table 3

Inotrope and saline bolus use throughout the experiment

	Normothermia		Hypothermia	
	Mean	(SD)	Mean	(SD)
Dopamine (μg/kg/min)	10.1	(4.8)	15.6	(6.4)
Dobutamine (μg/kg/min)	2.8	(4.5)	4.5	(6.9)
Noradrenaline (ng/kg/min)	16	(37)	96	(149)
Adrenaline (ng/kg/min)	0	(0)	484	(811)
10ml/kg Saline bolus (n)	0.7	(0.8)	0.8	(1.3)

No comparisons were p<0.05